RA patients in remission should continue taking TNF inhibitors to prevent flare-ups

New research at ACR Convergence 2023, the annual meeting of the American College of Rheumatology (ACR), found that patients with rheumatoid arthritis (RA) in sustained remission who stopped taking TNF inhibitors (TNFi) had significantly more flares and lower Boolean 2.0 remission rates compared to those who continued treatment. Boolean 2.0 is a revised definition for…